Detailed analysis of whether Lynparza (Lipuzhuo) is a chemotherapy drug or a targeted drug

Olaparib (Olaparib) is a typical targeted drug, not a traditional chemotherapy drug. It is a PARP (polyadenosine diphosphate ribose polymerase) inhibitor that inhibits tumor growth by targeting the ability of tumor cells to repair DNA damage. This type of drug is different from traditional chemotherapy in that it does not directly kill rapidly dividing cells, but selectively intervenes in the molecular pathways of tumors, making it more precise.

Compared with chemotherapy, olaparib has a milder mechanism of action and relatively fewer side effects. Chemotherapy drugs often affect normal cells and cause significant adverse reactions such as hair loss, nausea, and decreased immunity. Lynparza mainly inhibits PARP enzymes, making BRCA-mutated tumor cells unable to repair DNA, leading to cell apoptosis. Because of this mechanism, it is particularly effective for people with specific gene mutations and is often used in the treatment of ovarian cancer, breast cancer, pancreatic cancer, etc.

In addition, olaparib is often used clinically as part of maintenance therapy or combination therapy. For patients whose disease is controlled after initial treatment, continued use of olaparib can prolong progression-free survival and significantly improve treatment outcomes in some patients. Due to its oral administration method, patients can complete treatment at home, greatly improving treatment convenience and compliance.

In general, olaparib is a new type of targeted drug that is different from traditional chemotherapy drugs. It provides more targeted and personalized treatment options by precisely intervening in the repair mechanism of tumor cells. With the popularization of genetic testing technology, more and more patients who meet specific mutation characteristics can benefit from this treatment, bringing new directions and hope for cancer treatment.

Reference materials:https://www.drugs.com/